Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

Company Overview

Vanda Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24-hour sleep-wake disorder in totally blind individuals and for night-time sleep disturbances in Smith–Magenis syndrome. The company also markets Firdapse (amifampridine), indicated for the treatment of Lambert–Eaton myasthenic syndrome. Both products exemplify Vanda’s expertise in rare and orphan diseases and reflect its ability to bring targeted therapies from concept to market.

Beyond its approved products, Vanda maintains a diversified clinical pipeline that includes VNP01 for the treatment of manic episodes in bipolar I or II disorder and other investigational compounds addressing depressive disorders, Parkinson’s disease, and additional CNS indications. The company leverages strategic partnerships and in-house expertise to advance these candidates through Phase II and III trials, with the goal of expanding its therapeutic portfolio and geographic reach.

Founded in 2003 and headquartered in Washington, D.C., Vanda Pharmaceuticals operates primarily in the United States and holds regulatory authorizations in Europe and other international markets. Since January 2014, Dr. Mihael Polymeropoulos has served as President and Chief Executive Officer, guiding the company through successful product launches and global expansion efforts. Vanda’s leadership team combines clinical, regulatory, and commercial experience to support its strategic growth in the CNS and rare disease arenas.

Key Stats

• Today's Range: $4.47 to $4.56
• 50-Day Range: $4.19 to $5.02
• 52-Week Range: $3.81 to $5.55
• Volume: 70,228 shs
• Average Volume: 555,703 shs
• Market Capitalization: $265.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Strong Buy

Vanda Pharmaceuticals Stock Analysis - MarketRank™

Vanda Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 166th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Vanda Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Vanda Pharmaceuticals has a consensus price target of $16.50, representing about 267.9% upside from its current price of $4.49.

Amount of Analyst Coverage

Vanda Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($1.12) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vanda Pharmaceuticals is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vanda Pharmaceuticals is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vanda Pharmaceuticals has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.38% of the float of Vanda Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Vanda Pharmaceuticals has recently increased by 1.77%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vanda Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vanda Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.77

Percentage of Shares Shorted

8.38% of the float of Vanda Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Vanda Pharmaceuticals has recently increased by 1.77%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Vanda Pharmaceuticals has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

Search Interest

3 people have searched for VNDA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vanda Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,130.00 in company stock.

Percentage Held by Insiders

Only 8.90% of the stock of Vanda Pharmaceuticals is held by insiders.

Percentage Held by Institutions

88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed this year?

Vanda Pharmaceuticals' stock was trading at $4.79 at the start of the year. Since then, VNDA stock has decreased by 6.4% and is now trading at $4.4850.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its earnings results on Thursday, July, 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.12. The biopharmaceutical company had revenue of $52.59 million for the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative trailing twelve-month return on equity of 12.89%.
Read the conference call transcript.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' top institutional shareholders include Acadian Asset Management LLC (2.93%), Geode Capital Management LLC (2.86%), Krensavage Asset Management LLC (1.73%) and Connor Clark & Lunn Investment Management Ltd. (1.47%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Kevin Patrick Moran, Joakim Wijkstrom, Stephen Ray Mitchell and Timothy Williams.
View institutional ownership trends.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VNDA
• CIK: 1347178
• Web: www.vandapharma.com
• Phone: (202) 734-3400
• Fax: 202-296-1450
• Employees: 290
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Vanda Pharmaceuticals: $16.50
• High Price Target: $20.00
• Low Price Target: $13.00
• Potential Upside/Downside: +262.6%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.90 million
• Net Margins: -32.90%
• Pretax Margin: -41.77%
• Return on Equity: -12.89%
• Return on Assets: -10.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.25
• Quick Ratio: 3.23

Sales & Book Value

• Annual Sales: $198.77 million
• Price / Sales: 1.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.24 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 59,090,000
• Free Float: 53,830,000
• Market Cap: $268.86 million
• Optionable: Optionable
• Beta: 0.74